Harvey Partners’s Idexx Laboratories IDXX Stock Holding History

Harvey Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,500	Closed	-$848K	–	41
2020 Q1	$848K	Buy	+3,500	New	+$913K	0.77%	27

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Harvey Partners's IDXX Position: Q2 2020 in Review

Harvey Partners sold out of Idexx Laboratories (IDXX) in Q2 2020, closing a stake of 3,500 shares — an estimated $848K sold.

Harvey Partners first reported a position in IDXX in Q1 2020 and held it in 1 quarter. The position peaked at $848K in Q1 2020. 801 funds tracked by Wall St. Rank hold IDXX as of Q2 2020.

Harvey Partners reported no remaining Idexx Laboratories position as of Q2 2020 after selling out during the quarter.
Harvey Partners sold 3,500 Idexx Laboratories shares in Q2 2020, an estimated $848K.
Harvey Partners first reported a position in Idexx Laboratories in Q1 2020 and held it in 1 quarter.
Harvey Partners's Idexx Laboratories position peaked at $848K in Q1 2020.
801 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2020.

Based on Harvey Partners's 13F filing for Q2 2020, filed 14 Aug 2020.